VX-809

DRUG4 trials

Sponsors

Vertex Pharmaceuticals Incorporated

Conditions

Cystic Fibrosis

Phase 1

Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects

CompletedNCT00966602

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2009-09-30End: 2009-12-31Target: 24Updated: 2010-01-05

Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects

CompletedNCT01216046

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2010-10-31End: 2011-05-31Updated: 2012-01-18

Phase 2

Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation

CompletedNCT00865904

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2009-03-31End: 2009-12-31Updated: 2015-08-28

Phase 3

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

CompletedNCT02514473

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2015-07-31End: 2016-09-30Updated: 2017-10-23

Related Papers

S93 Effect of lumacaftor/ivacaftor on total, bronchiectasis, and air trapping computed tomography (ct) scores in children homozygous for f508del-cftr: exploratory imaging substudy

2017-11-152 citations

P254 Feasibility of ultrashort echo time (ute) mri to evaluate the effect of lumacaftor/ivacaftor therapy in children with cystic fibrosis (cf) homozygous for f508del

2017-11-15

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.

2017-06-09203 citations

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

2011-08-08392 citations